Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

MS-102: Navigating the MS Therapeutic Landscape (A CSPE Core Curriculum Series)

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

View the other Modules in this CSPE Core Curriculum Series:
  
MS-101: Pathogenesis, Diagnostic and Clinical Course Treatment Considerations in MS

MS-103: The Role of the Specialty Pharmacy Professional in Managing MS Treatment: Care Transitions, Patient Education/Adherence, and Financial Considerations

MS-104: Optimizing MS Treatment: Case Studies and Applications in Specialty Pharmacy Practice 

 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

 
 View more NASP/CSPE Activities

Activity Description

Multiple sclerosis (MS) affects an estimated 400,000 people in the U.S., with approximately 10,000 new cases reported every year. As a chronic and progressive neurologic disease that requires lifelong, dynamic treatment via costly, high-touch medications that also require special handling and storage, multiple sclerosis therapies are often delivered via specialty pharmacy programs.

The NASP/CSPE MS Core Curriculum Series is intended to increase specialty clinicians’ knowledge of the evolving MS treatment paradigm and provide the necessary professional education to counsel patients and caregivers on the myriad therapeutic options, routes of administration, and behavioral/clinical/financial variables that must be considered alongside drug therapy choices when treating MS across care settings. As the second installment in the four-module NASP/CSPE MS Core Curriculum Series, this activity provides an in-depth discussion of the various therapies used in the treatment of MS.

Learning Objectives

The target audience for this activity includes pharmacists and nurses caring for MS patients. Upon completion of this activity, participants will be able to:

  • Differentiate the “platform” Disease-Modifying Therapies (DMTs) and newer oral and injectable Multiple Sclerosis (MS) therapies with regard to efficacy, safety and tolerability, and immunological activity.
  • Recognize how the product is supplied and how to properly administer as well as store each disease-modifying therapy.
  • Outline the latest evidence-based therapeutic regimens for relapsing MS, including staging, sequencing, and combination treatment across care settings.

Faculty

Aimee M. Banks, PharmD, BCPS
Clinical Pharmacist
Vanderbilt University Medical Center
Multiple Sclerosis Clinic
Nashville, Tennessee

Brandon M. Markley, PharmD, BCPS
Clinical Pharmacist
Vanderbilt University Medical Center
Multiple Sclerosis Clinic
Nashville, Tennesee

Steering/Review Committee

Susan Allen, PharmD; Aimee Banks, PharmD; Joy Derwenskus, DO, MS; Stephanie LaPointe, PharmD; Brandon Markley, PharmD; Mel Nelson, PharmD; Stacey Ness, PharmD; Libin Philip, PharmD.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Aimee Banks and Brandon Markley have no relevant commercial and/or financial relationships to disclose. Joy Derwenskus has served as a Speaker and/or Consultant for EMD Serono, Genzyme, a Sanofi Company, Novartis, and Teva Pharmaceuticals USA. Susan Allen, Stephanie LaPointe, Melissa Nelson, Stacey Ness, and Libin Philip have no relevant commercial and/or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 11-02-2016
Expiration Date: 11-30-2017

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-16-336-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Nurses

This CE activity is jointly provided by ProCE, Inc. and Wild Iris Medical Education, Inc. This activity provides 1.0 contact hour of nurse CE credit.

Wild Iris Medical Education, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Funding

This activity is supported by educational grants from Bayer, Genzyme, a Sanofi Company, and Novartis.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.